Fungal infections and their treatment in the intensive care unit

Current Opinion in Critical Care

Volumn 12, Issue 5, 2006, Pages 464-469

  Sarosi, George A ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Azoles; Candidiasis; Coccidioidomycosis; Echinocandins; Fungal infection

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; BETA GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; CANDIDEMIA; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; FUNGAL MENINGITIS; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; LIVER TRANSPLANTATION; LUNG INFECTION; MENINGITIS; MYCOSIS; REVIEW; T LYMPHOCYTE; THORAX RADIOGRAPHY;

ANTIFUNGAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 33748439814     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000244128.92612.50     Document Type: Review

References (42)

1. Goodwin RA Jr, Loyd JE, DesPrez RM. Histoplasmosis in normal hosts. Medicine 1981; 60:231-266.
2. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immunodeficiency syndrome; clinical finds, diagnosis and treatment, and review of the literature. Medicine 1990; 69:361-374.
3. Johnson PC, Hamill RJ, Sarosi GA. Clinical review: progressive disseminated histoplasmosis in the AIDS patient. Semin Respir Infect 1989; 4:139-146.
4. Wheat LJ, Conolly-Stringfield PA, Kohler RB, et al. Histoplasma capsulatum polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 1989; 87:396-400.
5. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30:688-695.
6. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105-109.
7. Chu JH, Feudtner C, Heydon K, et al. Hospitalization for endemic mycoses: a population based national study. Clin Infect Dis 2006; 42:822-825.
8. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116:847-853.
9. Sanders JS, Sarosi GA, Nollet DJ, et al. Exfoliative cytology in the rapid diagnosis of pulmonary blastomycosis. Chest 1977; 72:193-196.
10. Lemos LB, Guo M, Baliga M. Blastomycosis: organ involvement and etiologic diagnosis. A review of 123 patients from Mississippi. Ann Diagn Pathol 2000; 4:391-406.
11. Martynovicz MA, Prakash UB. Pulmonary blastomycosis: an appraisal of diagnostic techniques. Chest 2002; 121:768-773.
12. Dismukes WE, Bradsher RW, Cloud GL. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93:489-497.
13. Dismukes WE. Antifungal therapy: lessons learned over the past 17 years. Clin Infect Dis 2006; 42:1289-1296. The best and most up-to-date discussion of the current state of the art for fungal infections.
14. Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006; 12:958-962. An extremely important new development, pointing out the extremely high frequency of acute coccidioidomycosis among patients with community-acquired pneumonia.
15. Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis 2006; 42:103-107. An authoritative and up-to-date discussion of the topic by the most experienced clinicians in the field.
16. Singh VR, Smith DK, Lawrence J, et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996; 23:563-568.
17. Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41:1174-1178. An excellent overview of the recent development.
18. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomised, double blind trial. Mycoses study group. Ann Intern Med 2000; 133:676-686.
19. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119:28-35.
20. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy of Coccidioides immmitis meningitis? Ann Inter Med 1996; 124:305-310.
21. Saag MS, Graybill RJ, Robert A, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-718.
22. Ecevit IZ, Clancy CJ, Schmalfuss IM, et al. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006; 42:1443-1447.
23. Fridkin SK. The changing face of fungal infections in healthcare settings. Clin Infect Dis 2005; 41:1455-1460. An excellent overview of the changing ecology of fungal infections.
24. Trick WE, Fridkin SK, Edwards JR, et al. Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630.
25. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38:311-320.
26. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42:1519-1527.
27. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of candida. Clin Microbiol Infect 2004; 10 (suppl 1):11-23.
28. Abi-Said D, Anaisse E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different candida species. Clin Infect Dis 1997; 24:1122-1128.
29. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3)β-D-Glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659. An important new development for improved diagnosis of opportunistic fungal infections.
30. Ostrosky-Zeichner L, Marr K, Rex JH, Cohen S. Amphotericin B: time for a new 'gold standard'. Clin Infect Dis 2003; 37:415-425.
31. Rex JH, Bennett JE, Sugar AM, et al., NIAID Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:125-130.
32. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in nonneutropenic patients. Eur J Clin Microbial Infect Dis 1997; 16:337-345.
33. Rex JH, Pappas PG, Karchmer AW, et al., NIAID Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-1228.
34. Kullberg BD, Sobel J, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B for candidemia in nonneutropenic patients: a randomized noninferiority trial. Lancet 2005; 366:1435-1440. Documenting the availability of another effective agent for the treatment of candidemia.
35. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029.
36. Ascioglu S, Rex JH, De Pauw B, et al., Invasive Fungal Infection Group of EORTC and NIAID Mycoses Study Group. Defining opportunitic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
37. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive Aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1217-1227. A carefully done analysis of the most frequently used new test for the diagnosis of aspergillosis.
38. Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis 2006; 42:1428-1430. A well written editorial comment on the topic.
39. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-1250.
40. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive Aspergillosis. N Engl J Med 2002; 347:408-415.
41. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive candida for invasive aspergillus infections in neutropenic patients. Cancer 2006; 106:466-473. Expanding the spectrum for the use of caspofungin.
42. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a casecontrol observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1360. An important complication of newer antifungal drugs.